Overview

Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma

Status:
Terminated
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sodium stibogluconate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Interferon may interfere with the growth of cancer cells. Giving sodium stibogluconate together with interferon may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of sodium stibogluconate when given together with interferon in treating patients with advanced solid tumors, lymphoma, or myeloma.
Phase:
Phase 1
Details
Lead Sponsor:
The Cleveland Clinic
Collaborator:
National Cancer Institute (NCI)
Treatments:
Antimony Sodium Gluconate
Interferon alpha-2
Interferon-alpha
Interferons